 "Dr Reddy's Q1 net down 76% at Rs 154 cr")
Dr Reddy’s Laboratories was up 3% at Rs 2,722 on BSE in intra-day trade after the company on Friday announced that the US drug regulator has completed the audit of active pharmaceutical ingredients (APIs) manufacturing plant at Srikakulam special economic zone (SEZ) in Andhra Pradesh with no observations.
At 09:38 am; the stock was up 2.7% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex. A combined 178,690 shares changed hands on the counter on BSE and NSE so far.
On March 22, 2017, the stock of Dr Reddy’s Laboratories hit an over two-year low of Rs 2,560 on BSE in intra-day trade after the drug maker on March 9 said the USFDA issued a Form 483 with 13 observations for the company’s formulation manufacturing facility at Duwada, Visakhapatnam.
At 09:38 am; the stock was up 2.7% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex. A combined 178,690 shares changed hands on the counter on BSE and NSE so far.
On March 22, 2017, the stock of Dr Reddy’s Laboratories hit an over two-year low of Rs 2,560 on BSE in intra-day trade after the drug maker on March 9 said the USFDA issued a Form 483 with 13 observations for the company’s formulation manufacturing facility at Duwada, Visakhapatnam.
